Notable Expands Executive Leadership Team with Appointment of Dr. Kevin Lynch as Chief Business Officer
—Industry Dealmaker Joins Notable to Accelerate In-licensing Strategy to Fuel Predictive Precision Platform and Pipeline—
FOSTER CITY, Calif.--(BUSINESS WIRE)--#drugdevelopment--Notable Labs, Inc. (Notable), a clinical-stage platform therapeutics company, announced the appointment of Kevin Lynch, Ph.D., MBA, as Chief Business Officer. Dr. Lynch has decades of deal-making experience within pharma, and recently led extensive business development operations as Chief Business Officer at Recursion and as Vice President of Business Development at VIR Biotechnology. Dr. Lynch will serve on the executive leadership team and will oversee Notable’s business and corporate development as well as corporate alliance management activities.
“Kevin has an impressive record of deal-making and long-standing relationships across the life sciences industry, and we are thrilled to welcome him to our team,” noted Thomas Bock, M.D., Chief Executive Officer of Notable. “He joins us at an incredibly exciting time at Notable, where we are advancing our clinical-stage oncology pipeline that we believe is poised to deliver remarkable results through our predictive precision medicines platform.”
“What has impressed me most is the combination of Notable’s experienced team across therapeutics, diagnostics and engineering together with its predictive platform and clinical precision medicine pipeline,” noted Dr. Lynch, Chief Business Officer. “I know first-hand that there is an abundance of promising, yet stalled, oncology assets that are primed for great success should there be a reliable way to match them with a known responsive patient population. I am hugely excited about Notable’s proprietary approach to do just that.”
Dr. Lynch brings to Notable over 25 years of industry experience at leading pharmaceutical and biotechnology companies and has led and executed a number of global, multibillion-dollar corporate transactions, including in-licenses, out-licenses, strategic partnerships, royalty monetization and industry-leading M&A activity. Dr. Lynch serves as an executive advisor to several biotechnology companies. In his over 20-year tenure at Abbott/AbbVie, Dr. Lynch executed a vast array of corporate transactions, and as Vice President, Search and Evaluation, oversaw search, evaluation and due diligence of all global business development opportunities, including academics, technologies, venture and M&A.
Dr. Lynch holds a Ph.D. in Microbiology from Penn State and an MBA from Northwestern.
Notable is a clinical-stage platform therapeutics company designing and delivering predictive precision medicines, a new class of medicines. Notable aims to be the leader in predictive precision medicine and revolutionize the way in which patients seek and receive treatments that work best for them – patient by patient and cancer by cancer. By transforming historical standards of care, Notable expects to provide dramatic impact for patients and the healthcare community.
Notable’s proprietary predictive precision medicines platform bio-simulates a patient’s cancer treatment and predicts whether a patient will respond to a specific cancer treatment. Using its high-fidelity platform, Notable can identify and select clinically responsive patients prior to their treatment and fast-track clinical development in this patient population. Notable has created a targeted, triple de-risked in-licensing strategy to deliver a product’s medical impact and commercial value faster, higher, and more likely than traditional drug development.
Investors in Notable include B Capital Group, Lifeforce Capital, Builders VC, Founders Fund, Lightspeed Venture Partners, Y Combinator, First Round Capital as well as 11.2 Capital, Refactor Capital, Upside Partnership, and Fuel Ventures.